DRDaniel Rudmann

Daniel Rudmann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daniel Rudmann has a total of 76 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Artificial intelligence in veterinary diagnostic histopathology: Concepts, applications, and clinical implementation

    by Judit M. Wulcan, Jonatan Wulcan, Kevin L. Jacques, Daniel G. Rudmann, J. Rachel Reader, Stefan M. Keller

    Artificial intelligence (AI) in human diagnostic histopathology has advanced rapidly, but clinical adoption has lagged behind research. Veterinary diagnostic pathology, being less regulated, could adopt AI faster, but the extent of its integration into diagnostic laboratories is unknown. This article combines a narrative introduction to key concepts, a scoping review of published applications, and an exploratory survey of diagnostic laboratories to provide an overview of AI in veterinary diagnostic histopathology. The narrative review highlights emerging approaches, including vision transformer-based foundation models and self-supervised learning, which may improve generalizability and reduce data requirements, although adaptation to the veterinary context remains challenging. The scoping review identified 34 studies published through a September 5, 2025, literature search, indicating steady but limited growth. Most used convolutional neural networks for relatively low-level tasks such as cell quantification, area measurement, and diagnosis. The survey had a low response rate (2 of 5 laboratories). Both respondents recognized potential benefits of AI. One laboratory had incorporated 2 AI models into routine diagnostic workflows and was evaluating additional applications, while the other had not yet implemented AI but was actively considering several models. Reported barriers included generalizability, latency, and cost. Overall, AI research in veterinary diagnostic histopathology is growing, but clinical adoption remains incompletely characterized. While less restrictive regulation may allow faster uptake than in human medicine, the lack of oversight places responsibility for validation on laboratories and pathologists. For trustworthy implementation, veterinary pathologists must understand AI fundamentals, and the field should prioritize standards for validation, transparency, and reporting.

  • Complex In Vitro Model Characterization for Context of Use in Toxicologic Pathology: Use Cases by Collaborative Teams of Biologists, Bioengineers, and Pathologists

    by Nadine Stokar-Regenscheit, Luisa Bell, Brian Berridge, Daniel Rudmann, Danilo Tagle, Passley Hargrove-Grimes, Dirk Schaudien, Kerstin Hahn, Julia Kühnlenz, Randolph S. Ashton, et al.

    Complex in vitro models (CIVMs) offer the potential to increase the clinical relevance of preclinical efficacy and toxicity assessments and reduce the reliance on animals in drug development. The European Society of Toxicologic Pathology (ESTP) and Society for Toxicologic Pathology (STP) are collaborating to highlight the role of pathologists in the development and use of CIVM. Pathologists are trained in comparative animal medicine which enhances their understanding of mechanisms of human and animal diseases, thus allowing them to bridge between animal models and humans. This skill set is important for CIVM development, validation, and data interpretation. Ideally, diverse teams of scientists, including engineers, biologists, pathologists, and others, should collaboratively develop and characterize novel CIVM, and collectively assess their precise use cases (context of use). Implementing a morphological CIVM evaluation should be essential in this process. This requires robust histological technique workflows, image analysis techniques, and needs correlation with translational biomarkers. In this review, we demonstrate how such tissue technologies and analytics support the development and use of CIVM for drug efficacy and safety evaluations. We encourage the scientific community to explore similar options for their projects and to engage with health authorities on the use of CIVM in benefit-risk assessment.


  • Open Access

    Building a nonclinical pathology laboratory of the future for pharmaceutical research excellence

    by D.G. Rudmann, L. Bertrand, A. Zuraw, J. Deiters, M. Staup, Y. Rivenson, J. Kuklyte


  • Scientific and Regulatory Policy Committee Points to Consider: Primary Digital Histopathology Evaluation and Peer Review for Good Laboratory Practice (GLP) Nonclinical Toxicology Studies

    by Thomas Forest, Famke Aeffner, Dinesh S. Bangari, Bhupinder Bawa, Jonathan Carter, James Fikes, Wanda High, Shim-Mo Hayashi, Matthew Jacobsen, LuAnn McKinney, et al.

    The Society of Toxicologic Pathology’s Scientific and Regulatory Policy Committee formed a working group to consider the present and future use of digital pathology in toxicologic pathology in general and specifically its use in primary evaluation and peer review in Good Laboratory Practice (GLP) environments. Digital histopathology systems can save costs by reducing travel, enhancing organizational flexibility, decreasing slide handling, improving collaboration, increasing access to historical images, and improving quality and efficiency through integration with laboratory information management systems. However, the resources to implement and operate a digital pathology system can be significant. Given the magnitude and risks involved in the decision to adopt digital histopathology, this working group used pertinent previously published survey results and its members’ expertise to create a Points-to-Consider article to assist organizations with building and implementing digital pathology workflows. With the aim of providing a comprehensive perspective, the current publication summarizes aspects of digital whole-slide imaging relevant to nonclinical histopathology evaluations, and then presents points to consider applicable to both primary digital histopathology evaluation and digital peer review in GLP toxicology studies. The Supplemental Appendices provide additional tabulated resources.


  • Scientific and Regulatory Policy Committee Brief Communication: 2019 Survey on Use of Digital Histopathology Systems in Nonclinical Toxicology Studies

    by Thomas Forest, Famke Aeffner, Dinesh S. Bangari, Bhupinder Bawa, Jonathan Carter, James Fikes, Wanda B. High, Shim-Mo Hayashi, Matthew Jacobsen, LuAnn McKinney, et al.

    Histopathologic evaluation and peer review using digital whole-slide images (WSIs) is a relatively new medium for assessing nonclinical toxicology studies in Good Laboratory Practice (GLP) environments. To better understand the present and future use of digital pathology in nonclinical toxicology studies, the Society of Toxicologic Pathology (STP) formed a working group to survey STP members with the goal of creating recommendations for implementation. The survey was administered in December 2019, immediately before the COVID-19 pandemic, and the results suggested that the use of digital histopathology for routine GLP histopathology assessment was not widespread. Subsequently, in follow-up correspondence during the pandemic, many responding institutions either began investigating or adopting digital WSI systems to reduce employee exposure to COVID-19. Therefore, the working group presents the survey results as a pre-pandemic baseline data set. Recommendations for use of WSI systems in GLP environments will be the subject of a separate publication.


  • Utilizing Whole Slide Images for the Primary Evaluation and Peer Review of a GLP-Compliant Rodent Toxicology Study

    by Matt Jacobsen, Arthur Lewis, James Baily, Alain Fraser, Dan Rudmann, Shane Ryan

    The approach undertaken to deliver a Good Laboratory Practice (GLP) validation of whole slide images (WSIs) and the associated workflow for the digital primary evaluation and peer review of a GLP-compliant rodent inhalation toxicity study is described. The contract research organization (CRO) undertook validation of the slide scanner, scanner software, and associated database software. This provided a GLP validated environment within the database software for the primary histopathologic evaluation using WSI and viewed with the database software web viewer. The CRO also validated a cloud-based digital pathology platform that supported the upload and transfer of WSI and metadata to a cache within the sponsor's local area network. The sponsor undertook a separate GLP validation of the same cloud-based digital pathology platform to cover the download and review of the WSI. The establishment of a fit-for-purpose GLP-compliant workflow for WSI and successful deployment for the digital primary evaluation and peer review of a large GLP toxicology study enabled flexibility in accelerated global working and potential future reuse of digitized data for advanced artificial intelligence and machine learning image analysis.


  • Mini Review: The Last Mile—Opportunities and Challenges for Machine Learning in Digital Toxicologic Pathology

    by Oliver C. Turner, Brian Knight, Aleksandra Zuraw, Geert Litjens, Daniel G. Rudmann

    The 2019 manuscript by the Special Interest Group on Digital Pathology and Image Analysis of the Society of Toxicologic pathology suggested that a synergism between artificial intelligence (AI) and machine learning (ML) technologies and digital toxicologic pathology would improve the daily workflow and future impact of toxicologic pathologists globally. Now 2 years later, the authors of this review consider whether, in their opinion, there is any evidence that supports that thesis. Specifically, we consider the opportunities and challenges for applying ML (the study of computer algorithms that are able to learn from example data and extrapolate the learned information to unseen data) algorithms in toxicologic pathology and how regulatory bodies are navigating this rapidly evolving field. Although we see similarities with the “Last Mile” metaphor, the weight of evidence suggests that toxicologic pathologists should approach ML with an equal dose of skepticism and enthusiasm. There are increasing opportunities for impact in our field that leave the authors cautiously excited and optimistic. Toxicologic pathologists have the opportunity to critically evaluate ML applications with a “call-to-arms” mentality. Why should we be late adopters? There is ample evidence to encourage engagement, growth, and leadership in this field.


  • Developing a Qualification and Verification Strategy for Digital Tissue Image Analysis in Toxicological Pathology

    by Aleksandra Zuraw, Michael Staup, Robert Klopfleisch, Famke Aeffner, Danielle Brown, Thomas Westerling-Bui, Daniel Rudmann

    Digital tissue image analysis is a computational method for analyzing whole-slide images and extracting large, complex, and quantitative data sets. However, as with any analysis method, the quality of generated results is dependent on a well-designed quality control system for the entire digital pathology workflow. Such system requires clear procedural controls, appropriate user training, and involvement of specialists to oversee key steps of the workflow. The toxicologic pathologist is responsible for reporting data obtained by digital image analysis and therefore needs to ensure that it is correct. To accomplish that, they must understand the main parameters of the quality control system and should play an integral part in its conception and implementation. This manuscript describes the most common digital tissue image analysis end points and potential sources of analysis errors. In addition, it outlines recommended approaches for ensuring quality and correctness of results for both classical and machine-learning based image analysis solutions, as adapted from a recently proposed Food and Drug Administration regulatory framework for modifications to artificial intelligence/machine learning-based software as a medical device. These approaches are beneficial for any type of toxicopathologic study which uses the described end points and can be adjusted based on the intended use of the image analysis solution.


  • Using Deep Learning Artificial Intelligence Algorithms to Verify N-Nitroso-N-Methylurea and Urethane Positive Control Proliferative Changes in Tg-RasH2 Mouse Carcinogenicity Studies

    by Daniel Rudmann, Jay Albretsen, Colin Doolan, Mark Gregson, Beth Dray, Aaron Sargeant, Donal O’sHea D, Jogile Kuklyte, Adam Power, Jenny Fitzgerald

    In Tg-rasH2 carcinogenicity mouse models, a positive control group is treated with a carcinogen such as urethane or N-nitroso-N-methylurea to test study validity based on the presence of the expected proliferative lesions in the transgenic mice. We hypothesized that artificial intelligence–based deep learning (DL) could provide decision support for the toxicologic pathologist by screening for the proliferative changes, verifying the expected pattern for the positive control groups. Whole slide images (WSIs) of the lungs, thymus, and stomach from positive control groups were used for supervised training of a convolutional neural network (CNN). A single pathologist annotated WSIs of normal and abnormal tissue regions for training the CNN-based supervised classifier using INHAND criteria. The algorithm was evaluated using a subset of tissue regions that were not used for training and then additional tissues were evaluated blindly by 2 independent pathologists. A binary output (proliferative classes present or not) from the pathologists was compared to that of the CNN classifier. The CNN model grouped proliferative lesion positive and negative animals at high concordance with the pathologists. This process simulated a workflow for review of these studies, whereby a DL algorithm could provide decision support for the pathologists in a nonclinical study.